FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Rachel Tyndale

Research Profile

Chemicals & Drugs

Activities & Behaviors

Physiology

Disorders

Tobacco Use Disorder

Anatomy

Co-author Network

Publications

TOP 3
Sharon Miksys; William M Perry; Susanne L T Cappendijk; Bin Zhao; Rachel F Tyndale
Nicotine kinetics in zebra finches in vivo and in vitro.
Sharon Miksys; Rachel F Tyndale
Cytochrome P450-mediated drug metabolism in the brain.
Meghan J Chenoweth; Jennifer O'Loughlin; Marie-Pierre Sylvestre; Rachel F Tyndale
CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Rachel Tyndale (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sharon Miksys; William M Perry; Susanne L T Cappendijk; Bin Zhao; Rachel F Tyndale
Nicotine kinetics in zebra finches in vivo and in vitro.
Drug metabolism and disposition: the biological fate of chemicals 2013;41(6):1240-6.
2013: Sharon Miksys; Rachel F Tyndale
Cytochrome P450-mediated drug metabolism in the brain.
Journal of psychiatry & neuroscience : JPN 2013;38(3):152-63.
2013: Meghan J Chenoweth; Jennifer O'Loughlin; Marie-Pierre Sylvestre; Rachel F Tyndale
CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers.
Pharmacogenetics and genomics 2013;23(4):232-5.
2013: Irina Esterlis; Jonas O Hannestad; Dorothy M Hatsukami; Frederic Bois; Kelly P Cosgrove; D Cyril D'Souza; Evgenia Perkins; John P Seibyl; Rachel F Tyndale; Stephanie S O'Malley
Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers.
The American journal of psychiatry 2013;170(4):399-407.
2013: Andy Z X Zhu; Neal L Benowitz; Dorothy K Hatsukami; Caryn Lerman; Caroline C Renner; Gary E Swan; Rachel F Tyndale
The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2013;22(4):708-18.
2013: Laurie Sellings; Rachel F Tyndale; Bin Zhao; Thomas Dixon-McDougall; Christina Nowak; Schreiber Pereira; Cheng Qian; Derek van der Kooy
Nicotine-motivated behavior in Caenorhabditis elegans requires the nicotinic acetylcholine receptor subunits acr-5 and acr-15.
The European journal of neuroscience 2013;37(5):743-56.
2013: Neal L Benowitz; Delia Dempsey; Rachel F Tyndale; Andy Z X Zhu; Peyton Jacob
Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.
Pharmacogenetics and genomics 2013;23(3):135-41.
2013: Ryan Ting-A-Kee; Rachel F Tyndale; Amine Bahi; Mary-Rose Bufalino; Jean-Luc Dreyer; Hector Vargas-Perez; Derek van der Kooy
Infusion of brain-derived neurotrophic factor into the ventral tegmental area switches the substrates mediating ethanol motivation.
The European journal of neuroscience 2013;37(6):996-1003.
2013: Babalola Faseru; Ron Krebill; Matthew S Mayo; Nicole L Nollen; Kolawole S Okuyemi; Jasjit S Ahluwalia; Neal L Benowitz; Won S Choi; Rachel F Tyndale; Lisa Sanderson Cox
Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial.
Addictive behaviors 2013;38(3):1796-803.
2013: Andrew W Bergen; David V Conti; Christopher K Edlund; Sharon Hall; Harold S Javitz; Ruth E Krasnow; Pui-Yan Kwok; Won Lee; Caryn Lerman; Jinghua Liu; Martha Michel; Denise Nishita; Timothy B Baker; Neal L Benowitz; Rachel F Tyndale; Gary E Swan
Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.
Pharmacogenetics and genomics 2013;23(2):94-103.
2013: Caroline C Renner; Rachel F Tyndale; Neal L Benowitz; Joni Jensen; Anne P Lanier; Bruce Lindgren; Mark Parascandola; Christi A Patten; Dorothy K Hatsukami
Tobacco use among southwestern Alaska Native people.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2013;15(2):401-6.
2013: Robert A Schnoll; Rachel F Tyndale; E Paul Wileyto; Frank T Leone; Neal L Benowitz
High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2013;15(2):348-54.
2013: Catherine A Wassenaar; Christopher I Amos; Qiong Dong; Margaret R Spitz; Rachel F Tyndale
Pilot Study of CYP2B6 Genetic Variation to Explore the Contribution of Nitrosamine Activation to Lung Carcinogenesis.
International journal of molecular sciences 2013;14(4):8381-92.
2013: Irina Esterlis; Jonas O Hannestad; Marc Laruelle; Marina R Picciotto; John P Seibyl; R Andrew Sewell; Rachel F Tyndale; Frederic Bois; Richard E Carson; Kelly P Cosgrove
Imaging changes in synaptic acetylcholine availability in living human subjects.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2013;54(1):78-82.
2013: Andy Z X Zhu; Clifford H Watson; Neal L Benowitz; Matthew J Binnington; Dorothy K Hatsukami; Anne P Lanier; Caroline C Renner; Connie S Sosnoff; Irina Stepanov; Rachel F Tyndale
Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation.
Carcinogenesis 2013;34(1):93-101.
2013: Neal L Benowitz; Delia Dempsey; Gideon St Helen; Rachel F Tyndale; Peyton Jacob
Dose-independent kinetics with low level exposure to nicotine and cotinine.
British journal of clinical pharmacology 2013;75(1):277-9.
2013: T Liu; Rachel F Tyndale; Hui Wang; Xiao-zhong Wen; Xue-Qing Yu; Wei Chen; S P David; Wei-qing Chen
Association between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers.
Journal of human hypertension 2013;27(1):24-30.
2012: A Z X Zhu; Jasjit S Ahluwalia; Neal L Benowitz; Lisa Sanderson Cox; Babalola Faseru; Nicole L Nollen; Kolawole S Okuyemi; Rachel F Tyndale
CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion.
Clinical pharmacology and therapeutics 2012;92(6):771-7.
2012: C S Ferguson; Sharon Miksys; Roberta Palmour; Rachel F Tyndale
Differential effects of nicotine treatment and ethanol self-administration on CYP2A6, CYP2B6 and nicotine pharmacokinetics in African green monkeys.
The Journal of pharmacology and experimental therapeutics 2012;343(3):628-37.
2012: W Lee; C Lerman; D Li; J Liu; G E Swan; P Thomas; Rachel F Tyndale; Neal L Benowitz; A W Bergen; David V Conti
Gender-stratified gene and gene-treatment interactions in smoking cessation.
The pharmacogenomics journal 2012;12(6):521-32.
2012: Ellen M McDonagh; Rachel F Tyndale; Catherine Wassenaar; Michelle Whirl-Carrillo; Russ B Altman; Sean P David; Teri E Klein
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.
Pharmacogenetics and genomics 2012;22(9):695-708.
2012: Amandeep Mann; Deborah C Mash; Sharon L Miksys; Andrea Gaedigk; Stephen J Kish; Rachel F Tyndale
The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients.
Neurobiology of aging 2012;33(9):2160-71.
2012: Gideon St Helen; Rachel F Tyndale; Victoria C Wing; Adel Aziziyeh; Delia Dempsey; Tony P George; Daniel F Heitjan; Peyton Jacob; Maria Novalen; Neal L Benowitz
Reproducibility of the nicotine metabolite ratio in cigarette smokers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2012;21(7):1105-14.
2012: Wonho Lee; Caryn Lerman; Riju Ray; Gary E Swan; Paul Thomas; Rachel F Tyndale; Neal L Benowitz; Andrew W Bergen; David V Conti
DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers.
Pharmacogenetics and genomics 2012;22(7):551-4.
2012: Matthew J Binnington; Andy Z X Zhu; Neal L Benowitz; Dorothy K Hatsukami; Anne P Lanier; Caroline C Renner; Rachel F Tyndale
CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people.
Pharmacogenetics and genomics 2012;22(6):429-40.
2012: Neal L Benowitz; Dorothy K Hatsukami; Anne P Lanier; Bruce Lindgren; Caroline C Renner; Connie S Sosnoff; Irina Stepanov; Rachel F Tyndale; Clifford H Watson; Peyton Jacob
Exposure to nicotine and carcinogens among Southwestern Alaskan Native cigarette smokers and smokeless tobacco users.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2012;21(6):934-42.
2012: Utkarsh Kohli; Leena Choi; E Wesley Ely; Eitan A Friedman; Mordechai Muszkat; Pratik Pandharipande; Mika Scheinin; Gbenga G Sofowora; C Michael Stein; Rachel F Tyndale; Alastair J J Wood; Daniel Kurnik
CYP2A6 genetic variation and dexmedetomidine disposition.
European journal of clinical pharmacology 2012;68(6):937-42.
2012: Deborah W Tang; Rachel F Tyndale; Lesley K Fellows; Brian Hello; Margaret Mroziewicz; Alain Dagher
Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI.
NeuroImage 2012;60(4):2136-43.
2012: Jibran Y Khokhar; Rachel F Tyndale
Rat brain CYP2B-enzymatic activation of chlorpyrifos to the oxon mediates cholinergic neurotoxicity.
Toxicological sciences : an official journal of the Society of Toxicology 2012;126(2):325-35.
2012: Tao Liu; Rachel F Tyndale; Hui Wang; Xue-Qing Yu; Qian Zhou; Wei Chen; Sean P David; Wei-Qing Chen
Relationship between amounts of daily cigarette consumption and abdominal obesity moderated by CYP2A6 genotypes in Chinese male current smokers.
Annals of behavioral medicine : a publication of the Society of Behavioral Medicine 2012;43(2):253-61.
2012: Lisa Sanderson Cox; Babalola Faseru; Matthew S Mayo; Nicole L Nollen; Kolawole S Okuyemi; Rachel F Tyndale; Neal L Benowitz; Won S Choi; Jasjit S Ahluwalia
Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.
Journal of the National Cancer Institute 2012;104(4):290-8.
2012: Sharon Miksys; K Uhl; Rachel F Tyndale
Twenty-first-century neuroscience: the potential for innovative therapies for brain disorders.
Clinical pharmacology and therapeutics 2012;91(2):153-7.
2012: Ian Mahar; Marissa Maheu; Rosemary C Bagot; Maria Antonietta Davoli; Sheng-Hai Huang; Sharon Miksys; Rachel F Tyndale; Claire-Dominique Walker; Tak Pan Wong; Naguib Mechawar
Developmental hippocampal neuroplasticity in a model of nicotine replacement therapy during pregnancy and breastfeeding.
PloS one 2012;7(5):e37219.
2011: Charmaine S Ferguson; Rachel F Tyndale
Cytochrome P450 enzymes in the brain: emerging evidence of biological significance.
Trends in pharmacological sciences 2011;32(12):708-14.
2011: C S Ferguson; Sharon Miksys; R Palmour; Rachel F Tyndale
Independent and combined effects of ethanol self-administration and nicotine treatment on hepatic CYP2E1 in African green monkeys.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(12):2233-41.
2011: Catherine A Wassenaar; Qingyi Wei; Christopher I Amos; Qiong Dong; Margaret R Spitz; Rachel F Tyndale
Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.
Journal of the National Cancer Institute 2011;103(17):1342-6.
2011: Mary Falcone; Christopher Jepson; Neal Benowitz; Andrew W Bergen; Angela Pinto; E Paul Wileyto; Don Baldwin; Rachel F Tyndale; Caryn Lerman; Riju Ray
Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2011;13(6):498-503.
2011: Tao Liu; Sean P David; Rachel F Tyndale; Hui Wang; Qian Zhou; Peng Ding; Yan-Hui He; Xue-Qing Yu; Wei Chen; Casey Crump; Xiao-zhong Wen; Wei-Qing Chen
Associations of CYP2A6 genotype with smoking behaviors in southern China.
Addiction (Abingdon, England) 2011;106(5):985-94.
2011: Jürgen Rehm; Norman Giesbrecht; Louis Gliksman; Kathryn Graham; Anh D Le; Robert E Mann; Robin Room; Brian Rush; Rachel F Tyndale; Samantha Wells
Addiction Research Centres and the Nurturing of Creativity. Substance abuse research in a modern health care centre: the case of the Centre for Addiction and Mental Health.
Addiction (Abingdon, England) 2011;106(4):689-97.
2011: Andrew A Strasser; Neal L Benowitz; Angela G Pinto; Kathy Z Tang; Stephen S Hecht; Steve G Carmella; Rachel F Tyndale; Caryn Lerman
Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011;20(2):234-8.
2011: Jibran Y Khokhar; Rachel F Tyndale
Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2011;36(3):692-700.
2011: John A Cunningham; Scott T Leatherdale; Peter L Selby; Rachel F Tyndale; Laurie Zawertailo; Vladyslav Kushnir
Randomized controlled trial of mailed Nicotine Replacement Therapy to Canadian smokers: study protocol.
BMC public health 2011;11():741.
2011: Lisa Sanderson Cox; Babalola Faseru; Matthew S Mayo; Ron Krebill; Tricia S Snow; Carrie A Bronars; Nicole L Nollen; Won S Choi; Kolawole S Okuyemi; Gary A Salzman; Neal L Benowitz; Rachel F Tyndale; Jasjit S Ahluwalia
Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.
Trials 2011;12():22.
2010: Margaret Mroziewicz; Rachel F Tyndale
Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment.
Addiction science & clinical practice 2010;5(2):17-29.
2010: M K Ho; David Goldman; A Heinz; Jaakko Kaprio; M J Kreek; M D Li; M R Munafò; Rachel F Tyndale
Breaking barriers in the genomics and pharmacogenetics of drug addiction.
Clinical pharmacology and therapeutics 2010;88(6):779-91.
2010: Sharon Miksys; Rachel F Tyndale
Neurodegenerative diseases: a growing challenge.
Clinical pharmacology and therapeutics 2010;88(4):427-30.
2010: Jibran Y Khokhar; Sharon L Miksys; Rachel F Tyndale
Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors.
Brain research 2010;1348():1-9.
2010: Nael Al Koudsi; Rachel F Tyndale
Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism.
Xenobiotica; the fate of foreign compounds in biological systems 2010;40(6):381-92.
2010: Amandeep Mann; Rachel F Tyndale
Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.
The European journal of neuroscience 2010;31(7):1185-93.
2010: Taryn E Grieder; Laurie Sellings; Hector Vargas-Perez; Ryan Ting-A-Kee; Eric C Siu; Rachel F Tyndale; Derek van der Kooy
Dopaminergic signaling mediates the motivational response underlying the opponent process to chronic but not acute nicotine.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2010;35(4):943-54.
2010: Nael Al Koudsi; Ewa B Hoffmann; Abbas Assadzadeh; Rachel F Tyndale
Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.
European journal of clinical pharmacology 2010;66(3):239-51.
2010: Jill C Mwenifumbo; Qian Zhou; Neal L Benowitz; Edward M Sellers; Rachel F Tyndale
New CYP2A6 gene deletion and conversion variants in a population of Black African descent.
Pharmacogenomics 2010;11(2):189-98.
2010: Jibran Y Khokhar; Charmaine S Ferguson; Andy Z X Zhu; Rachel F Tyndale
Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment.
Annual review of pharmacology and toxicology 2010;50():39-61.
2010: Laurie A Zawertailo; Rachel F Tyndale; Usoa E Busto; Edward M Sellers
Effect of metabolic blockade on the psychoactive effects of dextromethorphan.
Human psychopharmacology 2010;25(1):71-9.
2009: Man Ki Ho; Babalola Faseru; Won S Choi; Nicole L Nollen; Matthew S Mayo; Janet L Thomas; Kolawole S Okuyemi; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale
Utility and relationships of biomarkers of smoking in African-American light smokers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(12):3426-34.
2009: Andrew W Bergen; David V Conti; David Van Den Berg; Wonho Lee; Jinghua Liu; Dalin Li; Nan Guo; Huaiyu Mi; Paul D Thomas; Christina N Lessov-Schlaggar; Ruth E Krasnow; Yungang He; Denise Nishita; Ruhong Jiang; Jennifer McClure; Elizabeth Tildesley; Hyman Hops; Rachel F Tyndale; Neal L Benowitz; Caryn Lerman; Gary E Swan
Dopamine genes and nicotine dependence in treatment-seeking and community smokers.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(10):2252-64.
2009: Nael Al Koudsi; Jasjit S Ahluwalia; Shih-Ku Lin; Edward M Sellers; Rachel F Tyndale
A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.
The pharmacogenomics journal 2009;9(4):274-82.
2009: Paul D Thomas; Huaiyu Mi; Gary E Swan; Caryn Lerman; Neal Benowitz; Rachel F Tyndale; Andrew W Bergen; David V Conti
A systems biology network model for genetic association studies of nicotine addiction and treatment.
Pharmacogenetics and genomics 2009;19(7):538-51.
2009: Gary E Swan; Christina N Lessov-Schlaggar; Andrew W Bergen; Yungang He; Rachel F Tyndale; Neal L Benowitz
Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine.
Pharmacogenetics and genomics 2009;19(5):388-98.
2009: Jiang Yue; Jibran Khokhar; Sharon Miksys; Rachel F Tyndale
Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake.
European journal of pharmacology 2009;609(1-3):88-95.
2009: Robert A Schnoll; Freda Patterson; E Paul Wileyto; Rachel F Tyndale; Neal Benowitz; Caryn Lerman
Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study.
Pharmacology, biochemistry, and behavior 2009;92(1):6-11.
2009: Sharon Miksys; Rachel F Tyndale
Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(3):634-40.
2009: Jill C Mwenifumbo; Rachel F Tyndale
Molecular genetics of nicotine metabolism.
Handbook of experimental pharmacology 2009;(192):235-59.
2009: Riju Ray; Rachel F Tyndale; Caryn Lerman
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes.
Journal of neurogenetics 2009;23(3):252-61.
2008: Amandeep Mann; Sharon Miksys; Anna Lee; Deborah C Mash; Rachel F Tyndale
Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment.
Neuropharmacology 2008;55(7):1147-55.
2008: Masoumeh Emamghoreishi; Hamid-Reza Bokaee; Mojtaba Keshavarz; Abbas Ghaderi; Rachel F Tyndale
CYP2A6 allele frequencies in an Iranian population.
Archives of Iranian medicine 2008;11(6):613-7.
2008: David V Conti; Won Lee; Dalin Li; Jinghua Liu; David Van Den Berg; Paul D Thomas; Andrew W Bergen; Gary E Swan; Rachel F Tyndale; Neal L Benowitz; Caryn Lerman
Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation.
Human molecular genetics 2008;17(18):2834-48.
2008: Freda Patterson; Robert A Schnoll; E Paul Wileyto; Angela Pinto; Leonard H Epstein; Peter G Shields; Larry W Hawk; Rachel F Tyndale; Neal L Benowitz; Caryn Lerman
Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion.
Clinical pharmacology and therapeutics 2008;84(3):320-5.
2008: Jill C Mwenifumbo; Edward M Sellers; Rachel F Tyndale
Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2008;10(8):1319-25.
2008: Megan J Shram; Eric C K Siu; Zhaoxia Li; Rachel F Tyndale; Anh Dzung Lê
Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats.
Psychopharmacology 2008;198(2):181-90.
2008: Jill C Mwenifumbo; Nael Al Koudsi; Man Ki Ho; Qian Zhou; Ewa B Hoffmann; Edward M Sellers; Rachel F Tyndale
Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent.
Human mutation 2008;29(5):679-88.
2008: Eric C K Siu; Rachel F Tyndale
Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice.
The Journal of pharmacology and experimental therapeutics 2008;324(3):992-9.
2008: Man Ki Ho; Jill C Mwenifumbo; Bin Zhao; Elizabeth M J Gillam; Rachel F Tyndale
A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent.
Pharmacogenetics and genomics 2008;18(1):67-75.
2008: Jiang Yue; Sharon Miksys; Ewa Hoffmann; Rachel F Tyndale
Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course.
Journal of psychiatry & neuroscience : JPN 2008;33(1):54-63.
2008: Jill C Mwenifumbo; Christina N Lessov-Schlaggar; Q Zhou; Ruth E Krasnow; Gary E Swan; Neal L Benowitz; Rachel F Tyndale
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.
Clinical pharmacology and therapeutics 2008;83(1):115-21.
2007: Huijun Z Ring; Ana M Valdes; Denise M Nishita; Suman Prasad; Peyton Jacob; Rachel F Tyndale; Gary E Swan; Neal L Benowitz
Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism.
Pharmacogenetics and genomics 2007;17(12):1007-15.
2007: Jill C Mwenifumbo; Rachel F Tyndale
Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.
Pharmacogenomics 2007;8(10):1385-402.
2007: Anna M Lee; Christopher Jepson; Ewa Hoffmann; Leonard Epstein; Larry W Hawk; Caryn Lerman; Rachel F Tyndale
CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.
Biological psychiatry 2007;62(6):635-41.
2007: Tamara L Wall; Kerri Schoedel; Huijun Z Ring; Susan E Luczak; Denise M Katsuyoshi; Rachel F Tyndale
Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2007;9 Suppl 3():S459-74.
2007: Rachel F Tyndale; Jennifer I Payne; Alexandra L Gerber; Jack C Sipe
The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2007;144B(5):660-6.
2007: Jill C Mwenifumbo; Edward M Sellers; Rachel F Tyndale
Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking.
Drug and alcohol dependence 2007;89(1):24-33.
2007: Anna M Lee; Christopher Jepson; Peter G Shields; Neal L Benowitz; Caryn Lerman; Rachel F Tyndale
CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(6):1312-4.
2007: Andrew A Strasser; Viba Malaiyandi; Ewa Hoffmann; Rachel F Tyndale; Caryn Lerman
An association of CYP2A6 genotype and smoking topography.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2007;9(4):511-8.
2007: M K Ho; Rachel F Tyndale
Overview of the pharmacogenomics of cigarette smoking.
The pharmacogenomics journal 2007;7(2):81-98.
2007: Eric C K Siu; Rachel F Tyndale
Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice.
Molecular pharmacology 2007;71(3):826-34.
2007: Shannon G Matta; David J K Balfour; Neal L Benowitz; R Thomas Boyd; Jerry J Buccafusco; Anthony R Caggiula; Caroline R Craig; Allan C Collins; M Imad Damaj; Eric C Donny; Phillip S Gardiner; Sharon R Grady; Ulrike Heberlein; Sherry S Leonard; Edward Levin; Ronald J. Lukas; Athina Markou; Michael J Marks; Sarah E McCallum; Neeraja Parameswaran; Kenneth A Perkins; Marina R Picciotto; Maryka Quik; Jed E Rose; Adrian Rothenfluh; William R Schafer; Ian P Stolerman; Rachel F Tyndale; Jeanne M Wehner; Jeffrey M Zirger
Guidelines on nicotine dose selection for in vivo research.
Psychopharmacology 2007;190(3):269-319.
2007: Eric C K Siu; Rachel F Tyndale
Non-nicotinic therapies for smoking cessation.
Annual review of pharmacology and toxicology 2007;47():541-64.
2007: Janet Audrain-McGovern; Nael Al Koudsi; Daniel Rodriguez; E Paul Wileyto; Peter G Shields; Rachel F Tyndale
The role of CYP2A6 in the emergence of nicotine dependence in adolescents.
Pediatrics 2007;119(1):e264-74.
2007: M Imad Damaj; Eric C K Siu; E M Sellers; Rachel F Tyndale; Billy R Martin
Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice.
The Journal of pharmacology and experimental therapeutics 2007;320(1):250-7.
2006: Anna M Lee; Meenal Joshi; Jiang Yue; Rachel F Tyndale
Phenobarbital induces monkey brain CYP2E1 protein but not hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism.
European journal of pharmacology 2006;552(1-3):151-8.
2006: Neal L Benowitz; Gary E Swan; Peyton Jacob; Christina N Lessov-Schlaggar; Rachel F Tyndale
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Clinical pharmacology and therapeutics 2006;80(5):457-67.
2006: Viba Malaiyandi; Shari D Goodz; Edward M Sellers; Rachel F Tyndale
CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(10):1812-9.
2006: Maryka Quik; Neeraja Parameswaran; Sarah E McCallum; Tanuja Bordia; Shanshan Bao; Alison L McCormack; Amy Kim; Rachel F Tyndale; J William Langston; Donato A Di Monte
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.
Journal of neurochemistry 2006;98(6):1866-75.
2006: Anna M Lee; Jiang Yue; Rachel F Tyndale
In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African Green monkeys: induction by chronic nicotine treatment.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(9):1508-15.
2006: Anna M Lee; Rachel F Tyndale
Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.
Journal of psychopharmacology (Oxford, England) 2006;20(4 Suppl):7-14.
2006: Anna M Lee; Sharon Miksys; Rachel F Tyndale
Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein.
British journal of pharmacology 2006;148(6):786-94.
2006: Caryn Lerman; Rachel F Tyndale; Freda Patterson; E Paul Wileyto; Peter G Shields; Angela Pinto; Neal L Benowitz
Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.
Clinical pharmacology and therapeutics 2006;79(6):600-8.
2006: Nael Al Koudsi; Jill C Mwenifumbo; Edward M Sellers; Neal L Benowitz; Gary E Swan; Rachel F Tyndale
Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.
European journal of clinical pharmacology 2006;62(6):481-4.
2006: Igor Karp; Jennifer O'Loughlin; James Hanley; Rachel F Tyndale; Gilles Paradis
Risk factors for tobacco dependence in adolescent smokers.
Tobacco control 2006;15(3):199-204.
2006: Meenal Joshi; Rachel F Tyndale
Induction and recovery time course of rat brain CYP2E1 after nicotine treatment.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(4):647-52.
2006: Viba Malaiyandi; Caryn Lerman; Neal L Benowitz; Christopher Jepson; Freda Patterson; Rachel F Tyndale
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.
Molecular psychiatry 2006;11(4):400-9.
2006: Meenal Joshi; Rachel F Tyndale
Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine.
Neuropharmacology 2006;50(5):568-75.
2006: Eric C K Siu; Dieter B Wildenauer; Rachel F Tyndale
Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5.
Psychopharmacology 2006;184(3-4):401-8.
2006: Anna M Lee; Sharon Miksys; Roberta Palmour; Rachel F Tyndale
CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment.
Neuropharmacology 2006;50(4):441-50.
2006: Sarah E McCallum; Neeraja Parameswaran; Tanuja Bordia; Hong Fan; Rachel F Tyndale; J William Langston; J Michael McIntosh; Maryka Quik
Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment.
Journal of neurochemistry 2006;96(4):1028-41.
2006: Sharon Miksys; Rachel F Tyndale
Nicotine induces brain CYP enzymes: relevance to Parkinson's disease.
Journal of neural transmission. Supplementum 2006;(70):177-80.
2005: Nael Al Koudsi; Rachel F Tyndale
Genetic influences on smoking: a brief review.
Therapeutic drug monitoring 2005;27(6):704-9.
2005: Sharon Miksys; Connie Cheung; Frank J Gonzalez; Rachel F Tyndale
Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(10):1495-502.
2005: Jill C Mwenifumbo; Mark G Myers; Tamara L Wall; Shih-Ku Lin; Edward M Sellers; Rachel F Tyndale
Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method.
Pharmacogenetics and genomics 2005;15(3):189-92.
2005: Viba Malaiyandi; Edward M Sellers; Rachel F Tyndale
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.
Clinical pharmacology and therapeutics 2005;77(3):145-58.
2005: Sheri D Grabus; Billy R Martin; Angela M Batman; Rachel F Tyndale; Edward Sellers; M Imad Damaj
Nicotine physical dependence and tolerance in the mouse following chronic oral administration.
Psychopharmacology 2005;178(2-3):183-92.
2005: Gary E Swan; Neal L Benowitz; Christina N Lessov; Peyton Jacob; Rachel F Tyndale; Kirk Wilhelmsen
Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence.
Pharmacogenetics and genomics 2005;15(2):115-25.
2004: Jennifer O'Loughlin; Gilles Paradis; W Kim; Joseph R DiFranza; Garbis Meshefedjian; Elizabeth McMillan-Davey; S Wong; James Hanley; Rachel F Tyndale
Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.
Tobacco control 2004;13(4):422-8.
2004: Gary E Swan; Neal L Benowitz; Peyton Jacob; Christina N Lessov; Rachel F Tyndale; Kirk Wilhelmsen; Ruth E Krasnow; Mary R McElroy; Sharyn E Moore; Michelle Wambach
Pharmacogenetics of nicotine metabolism in twins: methods and procedures.
Twin research : the official journal of the International Society for Twin Studies 2004;7(5):435-48.
2004: Gail McKeown-Eyssen; Cornelia J Baines; David E C Cole; Nicole Riley; Rachel F Tyndale; Lynn Marshall; Vartouhi Jazmaji
Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR.
International journal of epidemiology 2004;33(5):971-8.
2004: Kerri A Schoedel; Ewa B Hoffmann; Yushu Rao; Edward M Sellers; Rachel F Tyndale
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
Pharmacogenetics 2004;14(9):615-26.
2004: Vincenzo De Luca; Albert H C Wong; Daniel J Muller; Gregory W H Wong; Rachel F Tyndale; James L Kennedy
Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2004;29(8):1522-6.
2004: Delia Dempsey; Piotr Tutka; Peyton Jacob; Faith Allen; Kerri Schoedel; Rachel F Tyndale; Neal L Benowitz
Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Clinical pharmacology and therapeutics 2004;76(1):64-72.
2004: Sharon Miksys; Rachel F Tyndale
The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics.
Drug metabolism reviews 2004;36(2):313-33.
2003: Edward M Sellers; Yamini Ramamoorthy; Marilyn V Zeman; Mirjana V Djordjevic; Rachel F Tyndale
The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2003;5(6):891-9.
2003: Jennifer O'Loughlin; Joseph R DiFranza; Rachel F Tyndale; Garbis Meshefedjian; Elizabeth McMillan-Davey; Paul B S Clarke; James Hanley; Gilles Paradis
Nicotine-dependence symptoms are associated with smoking frequency in adolescents.
American journal of preventive medicine 2003;25(3):219-25.
2003: Alina L Micu; Sharon Miksys; Edward M Sellers; Dennis R Koop; Rachel F Tyndale
Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism.
The Journal of pharmacology and experimental therapeutics 2003;306(3):941-7.
2003: Sharon Miksys; Caryn Lerman; Peter G Shields; Deborah C Mash; Rachel F Tyndale
Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.
Neuropharmacology 2003;45(1):122-32.
2003: Edward M Sellers; Rachel F Tyndale; Leona C Fernandes
Decreasing smoking behaviour and risk through CYP2A6 inhibition.
Drug discovery today 2003;8(11):487-93.
2003: Lisa A Howard; Jasjit S Ahluwalia; Shih-Ku Lin; Edward M Sellers; Rachel F Tyndale
CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence.
Pharmacogenetics 2003;13(6):321-8.
2003: Wenjiang Zhang; Yamini Ramamoorthy; Rachel F Tyndale; Edward M Sellers
Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(6):768-72.
2003: Lisa A Howard; Sharon Miksys; Ewa Hoffmann; Deborah C Mash; Rachel F Tyndale
Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics.
British journal of pharmacology 2003;138(7):1376-86.
2003: I Gafni; Usoa E Busto; Rachel F Tyndale; Howard L Kaplan; Edward M Sellers
The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo.
Journal of clinical psychopharmacology 2003;23(2):169-75.
2003: Kerri A Schoedel; Rachel F Tyndale
Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications.
Biochimica et biophysica acta 2003;1619(3):283-90.
2003: Rachel F Tyndale
Genetics of alcohol and tobacco use in humans.
Annals of medicine 2003;35(2):94-121.
2003: Kerri A Schoedel; Edward M Sellers; Roberta Palmour; Rachel F Tyndale
Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.
Molecular pharmacology 2003;63(1):96-104.
2002: Jennifer O'Loughlin; Joseph R DiFranza; J Tarasuk; Garbis Meshefedjian; Elizabeth McMillan-Davey; Gilles Paradis; Rachel F Tyndale; P Clarke; James Hanley
Assessment of nicotine dependence symptoms in adolescents: a comparison of five indicators.
Tobacco control 2002;11(4):354-60.
2002: Chun Xu; Shari D Goodz; Edward M Sellers; Rachel F Tyndale
CYP2A6 genetic variation and potential consequences.
Advanced drug delivery reviews 2002;54(10):1245-56.
2002: Karen Ahijevych; Rachel F Tyndale; Ravinder K Dhatt; Harrison G Weed; Kristine K Browning
Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2002;4(4):423-31.
2002: Sharon Miksys; Rachel F Tyndale
Drug-metabolizing cytochrome P450s in the brain.
Journal of psychiatry & neuroscience : JPN 2002;27(6):406-15.
2002: Sharon Miksys; Yushu Rao; Ewa Hoffmann; Deborah C Mash; Rachel F Tyndale
Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics.
Journal of neurochemistry 2002;82(6):1376-87.
2002: Yamini Ramamoorthy; Ai-Ming Yu; Nina Suh; Robert L Haining; Rachel F Tyndale; Edward M Sellers
Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.
Biochemical pharmacology 2002;63(12):2111-9.
2002: Wenjiang Zhang; Yamini Ramamoorthy; Rachel F Tyndale; Stanley D D Glick; Isabelle M Maisonneuve; Martin E Kuehne; Edward M Sellers
Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(6):663-9.
2002: David Pritzker; Anish Kanungo; Tansel Kilicarslan; Rachel F Tyndale; Edward M Sellers
Designer drugs that are potent inhibitors of CYP2D6.
Journal of clinical psychopharmacology 2002;22(3):330-2.
2002: Leona C Fernandes; Tansel Kilicarslan; Howard L Kaplan; Rachel F Tyndale; Edward M Sellers; Myroslava K Romach
Treatment of codeine dependence with inhibitors of cytochrome P450 2D6.
Journal of clinical psychopharmacology 2002;22(3):326-9.
2002: Lisa A Howard; Edward M Sellers; Rachel F Tyndale
The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence.
Pharmacogenomics 2002;3(2):185-99.
2002: Wenjiang Zhang; Yamini Ramamoorthy; Tansel Kilicarslan; Helma Nolte; Rachel F Tyndale; Edward M Sellers
Inhibition of cytochromes P450 by antifungal imidazole derivatives.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(3):314-8.
2002: Rachel F Tyndale; Edward M Sellers
Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.
Therapeutic drug monitoring 2002;24(1):163-71.
2002: C Xu; Y S Rao; B Xu; E Hoffmann; J Jones; Edward M Sellers; Rachel F Tyndale
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles.
Biochemical and biophysical research communications 2002;290(1):318-24.
2002: Shari D Goodz; Rachel F Tyndale
Genotyping human CYP2A6 variants.
Methods in enzymology 2002;357():59-69.
2001: Lisa A Howard; A L Micu; Edward M Sellers; Rachel F Tyndale
Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver.
The Journal of pharmacology and experimental therapeutics 2001;299(2):542-50.
2001: Kerri A Schoedel; Edward M Sellers; Rachel F Tyndale
Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain.
Biochemical pharmacology 2001;62(8):1025-36.
2001: Yamini Ramamoorthy; Rachel F Tyndale; Edward M Sellers
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.
Pharmacogenetics 2001;11(6):477-87.
2001: Wenjiang Zhang; Tansel Kilicarslan; Rachel F Tyndale; Edward M Sellers
Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(6):897-902.
2001: Tansel Kilicarslan; Robert L Haining; Allan E Rettie; Usoa E Busto; Rachel F Tyndale; Edward M Sellers
Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 1):460-5.
2001: JM Wong; Patricia A Harper; U A Meyer; K W Bock; K Morike; J Lagueux; P Ayotte; Rachel F Tyndale; Edward M Sellers; D K Manchester; Allan B Okey
Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro.
Pharmacogenetics 2001;11(1):85-94.
2000: Y Rao; E Hoffmann; Mohammad I Zia; L Bodin; M Zeman; Edward M Sellers; Rachel F Tyndale
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.
Molecular pharmacology 2000;58(4):747-55.
2000: K Kathiramalainathan; Howard L Kaplan; Myroslava K Romach; Usoa E Busto; NY Li; J Säwe; Rachel F Tyndale; Edward M Sellers
Inhibition of cytochrome P450 2D6 modifies codeine abuse liability.
Journal of clinical psychopharmacology 2000;20(4):435-44.
2000: Edward M Sellers; Howard L Kaplan; Rachel F Tyndale
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking.
Clinical pharmacology and therapeutics 2000;68(1):35-43.
2000: Sharon Miksys; E Hoffmann; Rachel F Tyndale
Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment.
Biochemical pharmacology 2000;59(12):1501-11.
2000: Sharon Miksys; Yushu Rao; Edward M Sellers; M Kwan; D Mendis; Rachel F Tyndale
Regional and cellular distribution of CYP2D subfamily members in rat brain.
Xenobiotica; the fate of foreign compounds in biological systems 2000;30(6):547-64.
2000: Myroslava K Romach; SV Otton; Gail R Somer; Rachel F Tyndale; Edward M Sellers
Cytochrome P450 2D6 and treatment of codeine dependence.
Journal of clinical psychopharmacology 2000;20(1):43-5.
2000: Edward M Sellers; Rachel F Tyndale
Mimicking gene defects to treat drug dependence.
Annals of the New York Academy of Sciences 2000;909():233-46.
1999: Rachel F Tyndale; Y Li; N Y Li; E Messina; Sharon Miksys; Edward M Sellers
Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(8):924-30.
1999: Rachel F Tyndale; D M Tomkins
Differences in propensity for drinking alcohol are reflected in subunit- and region-specific GABA(A) receptor levels.
Addiction biology 1999;4(3):309-16.
1998: M P Nowak; Edward M Sellers; Rachel F Tyndale
Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies.
Clinical pharmacology and therapeutics 1998;64(4):378-83.
1998: K Droll; K Bruce-Mensah; SV Otton; A Gaedigk; Edward M Sellers; Rachel F Tyndale
Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
Pharmacogenetics 1998;8(4):325-33.
1998: Laurie A Zawertailo; Howard L Kaplan; Usoa E Busto; Rachel F Tyndale; Edward M Sellers
Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study.
Journal of clinical psychopharmacology 1998;18(4):332-7.
1997: Rachel F Tyndale; Sanjiv Bhave; E Hoffmann; P L Hoffmann; Boris Tabakoff; A J Tobin; Richard W Olsen
Pentobarbital decreases the gamma-aminobutyric acidA receptor subunit gamma-2 long/short mRNA ratio by a mechanism distinct from receptor occupation.
The Journal of pharmacology and experimental therapeutics 1997;283(1):350-7.
1997: E S Messina; Rachel F Tyndale; Edward M Sellers
A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
The Journal of pharmacology and experimental therapeutics 1997;282(3):1608-14.
1997: M P Nowak; Rachel F Tyndale; Edward M Sellers
CYP2D6 phenotype and genotype in a Canadian Native Indian population.
Pharmacogenetics 1997;7(2):145-8.
1997: S Cheung; H Nolte; SV Otton; Rachel F Tyndale; P H Wu; Edward M Sellers
Simultaneous gas chromatographic determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine.
Journal of chromatography. B, Biomedical sciences and applications 1997;690(1-2):77-87.
1997: Denise M Tomkins; SV Otton; N Joharchi; N Y Li; R F Balster; Rachel F Tyndale; Edward M Sellers
Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats.
The Journal of pharmacology and experimental therapeutics 1997;280(3):1374-82.
1997: Edward M Sellers; SV Otton; Rachel F Tyndale
The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse.
NIDA research monograph 1997;173():6-26.
1996: Andrew C Charles; S K Kodali; Rachel F Tyndale
Intercellular calcium waves in neurons.
Molecular and cellular neurosciences 1996;7(5):337-53.
1995: Timothy Beischlag; A Marchese; James Meador-Woodruff; S P Damask; Brian F O'Dowd; Rachel F Tyndale; Hubert H M Van Tol; Philip Seeman; Hyman B Niznik
The human dopamine D5 receptor gene: cloning and characterization of the 5'-flanking and promoter region.
Biochemistry 1995;34(17):5960-70.
1995: V Greger; JH Knoll; E Woolf; K Glatt; Rachel F Tyndale; T M DeLorey; R W Olsen; Allan J Tobin; James M Sikela; Y Nakatsu
The gamma-aminobutyric acid receptor gamma 3 subunit gene (GABRG3) is tightly linked to the alpha 5 subunit gene (GABRA5) on human chromosome 15q11-q13 and is transcribed in the same orientation.
Genomics 1995;26(2):258-64.
1994: Tim G Hales; Rachel F Tyndale
Few cell lines with GABAA mRNAs have functional receptors.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1994;14(9):5429-36.
1994: Rachel F Tyndale; Tim G Hales; Richard W Olsen; Allan J Tobin
Distinctive patterns of GABAA receptor subunit mRNAs in 13 cell lines.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1994;14(9):5417-28.
1993: Y Nakatsu; Rachel F Tyndale; T M DeLorey; D Durham-Pierre; JM Gardner; H J McDanel; Q Nguyen; J Wagstaff; M Lalande; James M Sikela
A cluster of three GABAA receptor subunit genes is deleted in a neurological mutant of the mouse p locus.
Nature 1993;364(6436):448-50.
1992: SV Otton; Rachel F Tyndale; D Wu; T Inaba; Werner Kalow; Edward M Sellers
Catalytic and immunologic similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6).
Drug metabolism and disposition: the biological fate of chemicals 1992;20(1):1-5.
1991: Rachel F Tyndale; T Aoyama; F Broly; T Matsunaga; T Inaba; Werner Kalow; H V Gelboin; U A Meyer; F J Gonzalez
Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.
Pharmacogenetics 1991;1(1):26-32.
1991: Rachel F Tyndale; Roger K Sunahara; T Inaba; Werner Kalow; F J Gonzalez; Hyman B Niznik
Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.
Molecular pharmacology 1991;40(1):63-8.
1991: Rachel F Tyndale; Werner Kalow; T Inaba
Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
British journal of clinical pharmacology 1991;31(6):655-60.
1990: Rachel F Tyndale; T Inaba
Simultaneous determination of haloperidol and reduced haloperidol by gas chromatography using a megabore column with electron-capture detection: application to microsomal oxidation of reduced haloperidol.
Journal of chromatography 1990;529(1):182-8.
1990: Rachel F Tyndale; F J Gonzalez; James P Hardwick; Werner Kalow; T Inaba
Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry.
Pharmacology & toxicology 1990;67(1):14-8.
1990: Hyman B Niznik; Rachel F Tyndale; F R Sallee; F J Gonzalez; James P Hardwick; T Inaba; Werner Kalow
The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins.
Archives of biochemistry and biophysics 1990;276(2):424-32.
1989: Rachel F Tyndale; T Inaba; Werner Kalow
Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.
Drug metabolism and disposition: the biological fate of chemicals 1989;17(3):334-40.